A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Fibromun (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms FIBROSARC USA
- Sponsors Philogen
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 15 May 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.